Tianjin Life Science & Technology Co., Ltd. Assurance Report on the Deposit and Use of Raised Funds [2026] DAHUA Audit No. 0011002463
To all shareholders of Tianjin Life Science & Technology Co., Ltd.:
We have audited the accompanying "Special Report on the Deposit and Use of Raised Funds for 2025" (hereinafter referred to as the "Special Report on Raised Funds") of Tianjin Life Science & Technology Co., Ltd. (hereinafter referred to as "Life Science Pharma").
I. Responsibility of the Board of Directors
The responsibility of the Board of Directors of Life Science Pharma is to prepare the Special Report on Raised Funds in accordance with the "Supervision Guidelines No. 2 for Listed Companies – Regulatory Requirements for the Management and Use of Raised Funds by Listed Companies (2022 Revision)" issued by the China Securities Regulatory Commission, the "Self-Regulatory Guidelines No. 1 for Main Board Listed Companies – Standardized Operation" issued by the Shenzhen Stock Exchange, and relevant format guidelines, and to ensure that its content is true, accurate, and complete, and does not contain any false records, misleading statements, or major omissions.
II. Responsibility of the Certified Public Accountants
Our responsibility is to express an assurance opinion on the Special Report on Raised Funds of Life Science Pharma based on our performance of assurance work. We have performed assurance services in accordance with the "China Standards on Related Services No. 3101 – Assurance Services Other Than Audits or Reviews of Historical Financial Information" of the Chinese Institute of Certified Public Accountants. This standard requires us to plan and perform assurance work to obtain reasonable assurance about whether the Special Report on Raised Funds of Life Science Pharma is free from material misstatement.
During the assurance process, we performed procedures including obtaining an understanding, inquiry, inspection, recalculation, and other procedures that we considered necessary. We believe that our assurance work provides a reasonable basis for expressing our opinion.
III. Assurance Conclusion
We are of the opinion that the Special Report on Raised Funds of Life Science Pharma has been prepared, in all material respects, in accordance with the "Supervision Guidelines No. 2 for Listed Companies – Regulatory Requirements for the Management and Use of Raised Funds by Listed Companies (2022 Revision)" issued by the China Securities Regulatory Commission, the "Self-Regulatory Guidelines No. 1 for Main Board Listed Companies – Standardized Operation" issued by the Shenzhen Stock Exchange, and relevant format guidelines. In all material respects, it fairly reflects the deposit and use of raised funds of Life Science Pharma for the year 2025.
IV. Limitation on Users and Purpose of the Report
This report is intended solely for the purpose of disclosure in the annual report of Life Science Pharma and shall not be used for any other purpose. We agree that this report will be an integral part of the annual report of Life Science Pharma and will be submitted and disclosed externally along with other documents.
Da Hua Certified Public Accountants (Special General Partnership)
Chinese Certified Public Accountant: Li Xiangfan China · Beijing
Chinese Certified Public Accountant: Yan Xinzhi
March 24, 2026
Tianjin Life Science & Technology Co., Ltd. 2025 Special Report on the Deposit and Use of Raised Funds
Tianjin Life Science & Technology Co., Ltd. Special Report on the Deposit and Use of Raised Funds for 2025
I. Basic Situation of Raised Funds
With the approval of the China Securities Regulatory Commission (Document No. Zhengjianxiazhi[2010]371) and the consent of the Shenzhen Stock Exchange, the Company issued 46 million shares of common stock (A shares) to the public for the first time, with a par value of RMB 1 per share and an issue price of RMB 45 per share. As of April 16, 2010, the Company had raised a total of RMB 2,070,000,000.00. After deducting issuance expenses of RMB 62,301,336.76, the net amount of raised funds was RMB 2,007,698,663.24.